Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5520551 | 0.81 | NCF1 (0.42) | MAPTLMNAALDH1A1PKMMAPK1 | |
| SCHEMBL5513403 | 0.79 | MAPT (0.45) | MAPTLMNAALDH1A1CYP19A1PKM | |
| SCHEMBL5516334 | 0.78 | IDH1 (0.42) | MAPTLMNAALDH1A1PKMMAPK1 | |
| SCHEMBL4785913 | 0.72 | LMNA (0.62) | MAPTLMNAPKMMAPK1SMN1; SMN2 | |
| SCHEMBL5514672 | 0.72 | MAPT (0.51) | MAPTLMNAKMT2APOLB | |
| SCHEMBL5514349 | 0.69 | MAPT (0.51) | MAPTLMNAALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL9724203 | 0.66 | MAPT (0.63) | MAPTLMNAALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL5522979 | 0.66 | NOS3 (0.50) | MAPTPKMMAPK1SMN1; SMN2RXFP1 | |
| SCHEMBL27581090 | 0.65 | NCF1 (0.43) | PKMMAPK1SMN1; SMN2RXFP1HTT | |
| SCHEMBL5516240 | 0.65 | NOS1 (0.48) | MAPTLMNASMN1; SMN2HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166589-B2 | Quinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-01-23 | — | — | US | disclosed |
| US-20060148794-A1 | Neuropeptide Y antagonist; antiarthritic agents; cardiovascular disorders; antidiabetic agents; kidney disorders; eating disorders; obesity | KLUG MICHAEL G | 2006-07-06 | — | — | US | disclosed |
| US-7064134-B2 | Quinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-06-20 | — | — | US | disclosed |
| US-20060063758-A1 | Neuropeptide Y antagonist; antiarthritc agents; cardiovascular disorders; antidiabetic agents; kidney diseases; eating disorders; obesity | KLUG MICHAEL G | 2006-03-23 | — | — | US | disclosed |
| US-7012073-B2 | Quinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-03-14 | — | — | US | disclosed |
| US-20040259858-A1 | Quinoline derivatives | KLUG MICHAEL G (US) | 2004-12-23 | — | — | US | disclosed |
| US-6787558-B2 | NEUROPEPTIDE Y RECEPTOR ANTAGONISTS, FOR TREATING ARTHRITIS, CARDIOVASCULAR DISEASES, DIABETES, RENAL FAILURE, EATING DISORDERS AND OBESITY | HOFFMANN-LA ROCHE INC. | 2004-09-07 | — | — | US | disclosed |
| US-20030158179-A1 | Quinoline derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2003-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158179-A1 | Quinoline derivatives | RAB1A, GLS, REN | MAPT 4336/4885LMNA 2524/4885ALDH1A1 700/4885 |
| US-20060148794-A1 | Neuropeptide Y antagonist; antiarthritic agents; cardiovascular disorders; antidiabetic agents; kidney disorders; eating disorders; obesity | NPY1R, NPY2R, NPY4R | MAPT 4644/4885LMNA 2603/4885ALDH1A1 3610/4885 |
| US-20040259858-A1 | Quinoline derivatives | RAB1A, GLS, REN | MAPT 4336/4885LMNA 2524/4885ALDH1A1 700/4885 |
| US-20060063758-A1 | Neuropeptide Y antagonist; antiarthritc agents; cardiovascular disorders; antidiabetic agents; kidney diseases; eating disorders; obesity | NPY1R, NPY2R, NPY4R | MAPT 3290/4885LMNA 2424/4885ALDH1A1 4005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.